An FDA advisory panel on Monday voted in favor of donanemab as a treatment for early symptomatic Alzheimer’s disease.In a press conference on June 10, the Peripheral and Central Nervous System Drugs Advisory Committee ruled 11-0 that donanemab (Eli Lilly & Co.), a once-per-month, 30-minute infusion treatment, was effective in treating individuals with mild cognitive impairment and mild